AI
NBIX icon

Atom Investors’s Neurocrine Biosciences NBIX Stock Holding History

Atom Investors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,863
Closed -$611K – 751
2025
Q2 		$611K Buy
4,863
+1,048
+27% +$120K 0.05% 325
2025
Q1 		$422K Buy
+3,815
New +$483K 0.05% 316
2019
Q1 		– Sell
-40,511
Closed -$2.89M – 650
2018
Q4 		$2.89M Buy
+40,511
New +$3.88M 0.28% 75

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atom Investors's NBIX Position: Q3 2025 in Review

Atom Investors sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 4,863 shares — an estimated $611K sold.

Atom Investors first reported a position in NBIX in Q4 2018 and held it in 3 quarters. The position peaked at $2.89M in Q4 2018. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Atom Investors reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Atom Investors sold 4,863 Neurocrine Biosciences shares in Q3 2025, an estimated $611K.
  • Atom Investors first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 3 quarters.
  • Atom Investors's Neurocrine Biosciences position peaked at $2.89M in Q4 2018.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Atom Investors's 13F filing for Q3 2025, filed 14 Nov 2025.